Results from ONJCRI’s MoST-CIRCUIT clinical trial suggest that combination immunotherapy with nivolumab and ipilimumab is a promising avenue for hard-to-treat gallbladder cancer patients.
➡️ https://ow.ly/RLX450YT3pI
#ClinicalTrials #GallbladderCancer #BiliaryTractCancer #immunotherapy
